: The gut microbiome (GM) has emerged in the last few years as a main character in several diseases. In pediatric oncological patients, GM has a role in promoting the disease, modulating the effectiveness of therapies, and determining the clinical outcomes. The therapeutic course for most pediatric cancer influences the GM due to dietary modifications and several administrated drugs, including chemotherapies, antibiotics and immunosuppressants. Interestingly, increasing evidence is uncovering a role of the GM on drug pharmacokinetics and pharmacodynamics, defining a bidirectional relationship. Indeed, the pediatric setting presents some contrasts with respect to the adult, since the GM undergoes a constant multifactorial evolution during childhood following external stimuli (such as diet modification during weaning). In this review, we aim to summarize the available evidence of pharmacomicrobiomics in pediatric oncology.

Leardini, D., Venturelli, F., Baccelli, F., Cerasi, S., Muratore, E., Brigidi, P., et al. (2022). Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(23), 1-19 [10.3390/ijms232315387].

Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome

Leardini, Davide;Venturelli, Francesco;Baccelli, Francesco
;
Cerasi, Sara;Muratore, Edoardo;Brigidi, Patrizia;Pession, Andrea;Prete, Arcangelo;Masetti, Riccardo
2022

Abstract

: The gut microbiome (GM) has emerged in the last few years as a main character in several diseases. In pediatric oncological patients, GM has a role in promoting the disease, modulating the effectiveness of therapies, and determining the clinical outcomes. The therapeutic course for most pediatric cancer influences the GM due to dietary modifications and several administrated drugs, including chemotherapies, antibiotics and immunosuppressants. Interestingly, increasing evidence is uncovering a role of the GM on drug pharmacokinetics and pharmacodynamics, defining a bidirectional relationship. Indeed, the pediatric setting presents some contrasts with respect to the adult, since the GM undergoes a constant multifactorial evolution during childhood following external stimuli (such as diet modification during weaning). In this review, we aim to summarize the available evidence of pharmacomicrobiomics in pediatric oncology.
2022
Leardini, D., Venturelli, F., Baccelli, F., Cerasi, S., Muratore, E., Brigidi, P., et al. (2022). Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 23(23), 1-19 [10.3390/ijms232315387].
Leardini, Davide; Venturelli, Francesco; Baccelli, Francesco; Cerasi, Sara; Muratore, Edoardo; Brigidi, Patrizia; Pession, Andrea; Prete, Arcangelo; M...espandi
File in questo prodotto:
File Dimensione Formato  
ijms-23-15387.pdf

accesso aperto

Descrizione: Leardini et al.
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.26 MB
Formato Adobe PDF
1.26 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/918139
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact